Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Key terms include: $150 million upfront payment to Yao Pharma Up to $1.935 billion in development, regulatory, and commercial milestone payments Tiered royalties on future global sales Coverage across all therapeutic, diagnostic, and prophylactic indications for both human and veterinary use This structure positions the agreement as one of the larger oral-GLP-1 licensing deals in recent years
In addition, researchers will also need other materials for their lab, such as sterile syringes, needles, and alcohol swabs
Drugs like Wegovy , Ozempic , and Zepbound are in high demand
This transaction follows Pfizers recent effort to rebuild its obesity portfolio after discontinuing three previous GLP-1 candidates due to issues such as elevated liver enzymes or insufficient Phase 1 data
US$ 27.00
US$ 27.64
US$ 25.95
US$ 26.62
US$ 28.62
US$ 20.34
